Genomic & Biopharma News

AbbVie’s phase 2 PARP study misses survival endpoints; hopes rest on bigger phase 3
AbbVie’s phase 2 PARP study misses survival endpoints; hopes rest on bigger phase 3 badams Wed, 12/07/2016 - 04:02
Fierce Biotech, 2016-12-07 09:02:09

Scientists discover how motors maneuver cells' intricate roadway system
Much like motors power our cars, they also ensure that proteins get to the right place in our cells, and a wide variety of diseases - from cancer to heart problems - can result when they don't.
News Medical Life Sciences, 2016-12-07 08:58:23

Simple nutrition care program in hospitals could help reduce patient stays and readmission rates
While proper nutrition is vital to staying healthy, its importance becomes more critical for patients recovering in the hospital.
News Medical Life Sciences, 2016-12-07 08:45:50

China is narrowing the U.S. lead in cancer research
China is narrowing the U.S. lead in cancer research phil Wed, 12/07/2016 - 03:31
Fierce Biotech, 2016-12-07 08:31:35

Mount Sinai introduces first-ever Coursera course on HPV-associated oral and throat cancer
Mount Sinai's Departments of Academic Informatics and Technology and Otolaryngology - Head and Neck Surgery, in conjunction with the Office of Continuing Medical Education at the Icahn School of Medicine at Mount Sinai, have launched the first-ever Coursera course on HPV-associated oral and throat cancer.
News Medical Life Sciences, 2016-12-07 07:44:14

Lung cancer surgery survival rates on the rise
Survival rates following lung cancer surgery are continuing to rise as the number of operations to treat the disease increases, finds a new report published by the Royal College of Physicians (RCP) and the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS).
PharmaTimes, 2016-12-07 06:52:19

Higher maternal age of successful child bearing may be marker of healthy aging
Death and taxes have long been said to be the only two things guaranteed in life. Exactly when someone will die, in most instances, remains a mystery.
News Medical Life Sciences, 2016-12-07 06:45:04

US expands scope of Avastin in ovarian cancer
The US Food and Drug Administration has approved Roche-group Genentech's application to market Avastin for patients with a specific type of ovarian cancer.
PharmaTimes, 2016-12-07 06:34:20

EU green light for BMS’ Opdivo in blood cancer
EU regulators have issued a green light for the use of Bristol-Myers Squibb's Opdivo to treat the rare and often aggressive blood cancer classical Hodgkin lymphoma (cHL).
PharmaTimes, 2016-12-07 06:33:38